Dextroamphetamine

How Hard Is It to Find Dextroamphetamine in Stock?

Dextroamphetamine has a findability score of 35 out of 100, meaning it is frequently difficult to find in stock at pharmacies. The ongoing amphetamine shortage — which began in October 2022 — continues to significantly affect supply in 2026. Most experts expect ongoing supply challenges through at least mid-2026, with some manufacturers reporting that recovery is not expected until well into 2026.

While the DEA increased the Aggregate Production Quota for d-amphetamine to 26.5 million grams in October 2025, this increase has proven insufficient to meet growing demand. The FDA estimates that demand grew 6% from 2023 to 2024, and multiple manufacturers continue to report limited availability or complete stock-outs for various dosages. Many pharmacies report intermittent stock-outs, especially for certain strengths and the extended-release formulation.

If your pharmacy is out of stock, Medfinder can help you locate a pharmacy near you that currently has Dextroamphetamine available.

Who Can Prescribe Dextroamphetamine?

Because Dextroamphetamine is a Schedule II controlled substance, it must be prescribed by a licensed healthcare provider with DEA registration. Common prescribing specialties include:

• Psychiatrists — most commonly prescribe for ADHD and related conditions
• Primary Care / Family Medicine physicians
• Pediatricians — for children and adolescents with ADHD
• Neurologists — especially for narcolepsy
• Sleep Medicine specialists

Telehealth providers can also prescribe Dextroamphetamine, though regulations vary by state. Some states require an in-person visit for initial Schedule II prescriptions.

Is Dextroamphetamine a Controlled Substance?

Yes. Dextroamphetamine is classified as a Schedule II controlled substance by the DEA due to its high potential for abuse and dependence. This means:

• Prescriptions cannot be called in to a pharmacy — they require a written or electronic prescription
• No automatic refills — a new prescription is needed each time
• Pharmacies may impose quantity limits
• Some states have additional restrictions on telehealth prescribing

The FDA boxed warning notes that misuse of amphetamines may cause sudden death and serious cardiovascular events. Patients should take Dextroamphetamine exactly as prescribed.

Common Side Effects of Dextroamphetamine

• Decreased appetite and weight loss
• Insomnia or difficulty sleeping
• Dry mouth
• Increased heart rate
• Nervousness or anxiety
• Headache
• Dizziness
• Stomach pain
• Irritability and restlessness

Serious side effects that require immediate medical attention include chest pain, shortness of breath, signs of psychosis (hallucinations, paranoia), new or worsening mood/behavioral changes, and numbness or color changes in fingers and toes (Raynaud's phenomenon).

Final Thoughts on Dextroamphetamine

Dextroamphetamine remains an effective and widely prescribed treatment for ADHD and narcolepsy, but the ongoing stimulant shortage makes finding it in stock a real challenge for patients in 2026. With a findability score of just 35 out of 100, many patients are forced to call multiple pharmacies or go without their medication.

If you're struggling to find Dextroamphetamine, Medfinder can help you locate pharmacies with current stock near you — no more endless phone calls. You can also save money using discount cards like GoodRx and SingleCare, which can bring the cash price down to as low as $30–$45 for a 30-day supply of generic IR tablets.